Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology - PubMed (original) (raw)

Review

Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology

J J M Hoozemans et al. Curr Pharm Des. 2008.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the deposition of beta amyloid (Abeta) protein and the formation of neurofibrillary tangles. In addition, there is an increase of inflammatory proteins in the brains of AD patients. Epidemiological studies, indicating that non-steroidal anti-inflammatory drugs (NSAIDs) decrease the risk of developing AD, have encouraged the study on the role of inflammation in AD. The best-characterized action of most NSAIDs is the inhibition of cyclooxygenase (COX). The expression of the constitutively expressed COX-1 and the inflammatory induced COX-2 has been intensively investigated in AD brain and different disease models for AD. Despite these studies, clinical trials with NSAIDs or selective COX-2 inhibitors showed little or no effect on clinical progression of AD. The expression levels of COX-1 and COX-2 change in the different stages of AD pathology. In an early stage, when low-fibrillar Abeta deposits are present and only very few neurofibrillary tangles are observed in the cortical areas, COX-2 is increased in neurons. The increased neuronal COX-2 expression parallels and colocalizes with the expression of cell cycle proteins. COX-1 is primarily expressed in microglia, which are associated with fibrillar Abeta deposits. This suggests that in AD brain COX-1 and COX-2 are involved in inflammatory and regenerating pathways respectively. In this review we will discuss the role of COX-1 and COX-2 in the different stages of AD pathology. Understanding the physiological and pathological role of cyclooxygenase in AD pathology may facilitate the design of therapeutics for the treatment or prevention of AD.

PubMed Disclaimer

Cited by

Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease.
Manev H, Chen H, Dzitoyeva S, Manev R. Manev H, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):315-9. doi: 10.1016/j.pnpbp.2010.07.032. Epub 2010 Aug 5. Prog Neuropsychopharmacol Biol Psychiatry. 2011. PMID: 20691748 Free PMC article. Review.
Microglia as a cellular target of diclofenac therapy in Alzheimer's disease.
Stopschinski BE, Weideman RA, McMahan D, Jacob DA, Little BB, Chiang HS, Saez Calveras N, Stuve O. Stopschinski BE, et al. Ther Adv Neurol Disord. 2023 Feb 27;16:17562864231156674. doi: 10.1177/17562864231156674. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 36875711 Free PMC article. Review.
Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging.
Zimmer ER, Leuzy A, Benedet AL, Breitner J, Gauthier S, Rosa-Neto P. Zimmer ER, et al. J Neuroinflammation. 2014 Jul 8;11:120. doi: 10.1186/1742-2094-11-120. J Neuroinflammation. 2014. PMID: 25005532 Free PMC article. Review.
An evaluation of progressive amyloidogenic and pro-inflammatory change in the primary visual cortex and retina in Alzheimer's disease (AD).
Hill JM, Dua P, Clement C, Lukiw WJ. Hill JM, et al. Front Neurosci. 2014 Nov 12;8:347. doi: 10.3389/fnins.2014.00347. eCollection 2014. Front Neurosci. 2014. PMID: 25429256 Free PMC article. No abstract available.
Loss of cholinergic receptor muscarinic 1 impairs cortical mitochondrial structure and function: implications in Alzheimer's disease.
Sabbir MG, Swanson M, Albensi BC. Sabbir MG, et al. Front Cell Dev Biol. 2023 May 18;11:1158604. doi: 10.3389/fcell.2023.1158604. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37274741 Free PMC article.

Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology - PubMed (original) (raw)